Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
⚠️ Updated analysis. The primary endpoint (PFS) was previously reported. This analysis reports updated PFS and final overall survival at 7 years median follow-up (max 12 years).
🎯 Clinical Bottom Line
S0226 demonstrated that adding fulvestrant to anastrozole as first-line endocrine therapy for postmenopausal women with HR+ metastatic breast cancer significantly improved both progression-free survival and overall survival compared with anastrozole alone. The benefit was concentrated in patients without prior adjuvant endocrine therapy. This trial predates the CDK4/6 inhibitor era and used a lower-than-standard fulvestrant maintenance dose (250 mg vs current 500 mg).
Key Result: Median OS — 49.8 vs 42.0 months, HR 0.82 (95% CI 0.69–0.98; P=0.03)
Safety Signal: Grade 5 pulmonary emboli (2 patients) and cerebrovascular ischemic event (1 patient) in the combination arm. Overall grade 3 toxicity was similar between arms (15% vs 13%; P=0.47).
✅ Patient Eligibility
Must Have:
- ER+ or PR+ metastatic breast cancer
- Postmenopausal
- First-line metastatic setting (no prior chemo/hormonal/immunotherapy for metastatic disease)
- Zubrod performance status 0–2
Cannot Have:
- Prior therapy for metastatic disease
- Adjuvant chemotherapy or AI completed within 12 months of enrollment
💊 Dosing Quick Guide
Experimental Regimen
Anastrozole: Standard dose (not specified in publication) orally daily Fulvestrant: 500 mg IM day 1 (loading), then 250 mg days 14 and 28, then 250 mg every 28 days Duration: Until progression
⚠️ Note: Fulvestrant maintenance dose was 250 mg — lower than current standard of 500 mg.
Control Regimen
Anastrozole: Standard dose orally daily Crossover to fulvestrant strongly encouraged at progression.
Key Dose Modifications [2]
Per current FDA prescribing information — not trial protocol - Fulvestrant 500 mg is the current approved dose (not the 250 mg used in this trial) - No dose reductions for fulvestrant; hold for hepatic impairment per label - Monitor hepatic function per prescribing information
⚠️ Safety Snapshot
| Safety Metric | Combination (n=348) | Anastrozole Alone (n=338) |
|---|---|---|
| Grade 3 toxic effects | 51 (15%) | 43 (13%) |
| Discontinuation due to AE | 12 patients | 5 patients |
⚠️ Fatal events (combination arm): Pulmonary emboli (2 patients, grade 5), cerebrovascular ischemic event (1 patient, grade 5)
Grade 3 toxicities included musculoskeletal pain, fatigue, hot flashes, mood alterations, and GI symptoms at 1–4% frequency. No significant difference in grade 3 rates between arms (P=0.47).
📊 Key Numbers
Median follow-up: 7 years (patients without progression); max 12 years
| Outcome | Combination (n=349) | Anastrozole (n=345) | HR (95% CI) | p-value |
|---|---|---|---|---|
| Median PFS | 15.0 mo | 13.5 mo | 0.81 (0.69–0.94) | P=0.007 |
| Median OS | 49.8 mo | 42.0 mo | 0.82 (0.69–0.98) | P=0.03 |
| 5-year OS rate | 42% (37–47) | 33% (28–38) | — | — |
By prior endocrine therapy:
| Subgroup | Combination mOS | Anastrozole mOS | HR (95% CI) |
|---|---|---|---|
| No prior ET (n=414) | 52.2 mo | 40.3 mo | 0.73 (0.58–0.92) |
| Prior ET (n=280) | 48.2 mo | 43.5 mo | 0.97 (0.74–1.27) |
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| S0226 | Anastrozole + fulvestrant 250 mg vs anastrozole | Postmenopausal HR+ MBC, 1L | PFS | mOS 49.8 vs 42.0 mo; HR 0.82 | [1] |
| FACT | Anastrozole + fulvestrant 250 mg vs anastrozole | Postmenopausal HR+ MBC, 1L | TTP | See [5] | [5] |
| FALCON | Fulvestrant 500 mg vs anastrozole | Postmenopausal HR+/HER2− ABC, 1L, no prior ET | PFS | See [6] | [6] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
No prior endocrine therapy: OS HR 0.73 (95% CI 0.58–0.92) — clear benefit; drove the overall result Prior endocrine therapy: OS HR 0.97 (95% CI 0.74–1.27) — no benefit (interaction P=0.09) Endocrine sensitive: OS HR 0.79 (95% CI 0.65–0.95) — significant benefit Endocrine refractory: OS HR 1.08 (95% CI 0.65–1.80) — no benefit; numerically unfavorable Bone-only disease: OS HR 0.63 (95% CI 0.43–0.93) — pronounced benefit ≥10 yr diagnosis to metastasis: OS HR 0.69 (95% CI 0.49–0.98) — mOS 65.4 vs 49.7 months
Post hoc subgroup analyses were not powered for formal comparisons. CIs not adjusted for multiplicity. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Fulvestrant 500 mg approved for HR+ advanced breast cancer; anastrozole + fulvestrant combination not a distinct labeled indication [2] |
| EMA | Fulvestrant approved for advanced breast cancer |
⚠️ Verify current regulatory status before prescribing.
NCCN: CDK4/6 inhibitor + endocrine therapy is preferred 1L for HR+/HER2− MBC [3]. Endocrine monotherapy is an alternative. AI + fulvestrant combination is not a standard recommended 1L regimen in current guidelines.
⚡ Grey Zones
- Fulvestrant maintenance dose (250 mg) is lower than current standard (500 mg) — results may underestimate the true effect of combination therapy at optimal dosing
- Benefit concentrated in endocrine-naive patients (HR 0.73) with no benefit in prior ET group (HR 0.97) — interaction P=0.09, not definitive
- 45% crossover from anastrozole to fulvestrant at progression likely attenuates the OS difference
- Open-label design may bias investigator-assessed PFS
- Relevance in CDK4/6 inhibitor era is uncertain — this combination is not tested with or against CDK4/6 inhibitors
- Endocrine-refractory patients showed numerically worse outcomes with combination (HR 1.08)
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Mehta RS, Barlow WE, Albain KS, et al. Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. N Engl J Med. 2019;380:1226-1234. doi:10.1056/NEJMoa1811714
- Faslodex (fulvestrant) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
- Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367:435-444.
- Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30(16):1919-1925.
- Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON). Lancet. 2016;388(10063):2997-3005.